The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease.
 
Kamran A. Ahmed
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Youngchul Kim
No Relationships to Disclose
 
Michelle DeJesus
No Relationships to Disclose
 
Priya Kumthekar
Stock and Other Ownership Interests - Vivacitas Oncology
Consulting or Advisory Role - Biocept; Biocept; ElevateBio; Janssen; Novocure; Orbus Therapeutics
Research Funding - Angiochem; DNAtrix; Genentech; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Nicole Olivia Williams
No Relationships to Disclose
 
Joshua David Palmer
Honoraria - Huron Consulting; Varian Medical Systems
Consulting or Advisory Role - Novocure
Speakers' Bureau - Varian Medical Systems
Research Funding - Kroger; Ohio State University; Varian Medical Systems
 
Pierre Giglio
No Relationships to Disclose
 
Adrienne Ann Boire
Patents, Royalties, Other Intellectual Property - Boire A and J Massagué, inventors. Sloan Kettering Institute, assignee. Modulating Permeability Of The Blood Cerebrospinal Fluid Barrier. United States Provisional Application No.: 62/258,044. November 20, 2015. (Inst); Boire A, Chen Q and J Massagué, inventors. Sloan Kettering Institute, assignee. Methods for Treating Brain Metastasis. United States 10413522, awarded September 17, 2019. (Inst)
(OPTIONAL) Uncompensated Relationships - Evren Technologies
 
John Arrington
No Relationships to Disclose
 
Solmaz Sahebjam
Stock and Other Ownership Interests - Abbvie; Allergan
Consulting or Advisory Role - Boehringer Ingelheim; Merck
Research Funding - Bristol-Myers Squibb (Inst); Brooklyn ImmunoTherapeutics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Lilly
 
Marilin Rosa
No Relationships to Disclose
 
Hatem Hussein Soliman
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Immunomedics; Novartis; Puma Biotechnology; Seagen
Speakers' Bureau - Sanofi
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - Celeyad licensing agreement (Inst)
 
Hsiang-Hsuan Michael Yu
Honoraria - Brainlab
Consulting or Advisory Role - Abbvie; Novocure
 
Hyo S. Han
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Lilly
Research Funding - Abbvie (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Department of Defense (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Horizon Oncology Research (Inst); Marker Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); QuantumLeap Health (Inst); Seagen (Inst); Zymeworks (Inst)
 
Peter A. J. Forsyth
Honoraria - Abbvie; BTG; Novocure
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; BTG; Novocure; Tocagen; ZIOPHARM Oncology
Research Funding - Bankhead-Coley Cancer Research; Department of Defense; Florida Academic Cancer Center Alliance; NIH/NCI; Pfizer
Travel, Accommodations, Expenses - Abbvie; Bayer; Bristol-Myers Squibb; BTG; Inovio Pharmaceuticals; National Cancer Research Institute (NCRI); NCI; NIH; Physical Sciences Oncology Network